Zealand Pharma (CPSE:ZEAL) has drawn fresh attention after reporting positive multiple ascending dose Phase 1 data for its Kv1.3 blocker ZP9830. The results support continued development and the launch of a Phase 1b psoriasis study.
Despite today’s positive trial update and a 1-day share price return of 3.61% to DKK229.8, Zealand Pharma’s momentum has been weak. The 30-day share price return is down 18.51%, and the 1-year total shareholder return has declined 51.44%, even after several recent pipeline and partnership announcements.
Spot emerging opportunities beyond Zealand Pharma by scanning our hand-picked 616 high quality undiscovered gems with strong fundamentals that the wider market may be overlooking.Zealand Pharma’s sharp one day rebound contrasts with a much weaker 1 year track record, so the real question now is how much of the potential rerating is already reflected in the price.
Most Popular Narrative: 45% Undervalued
With Zealand Pharma last closing at DKK229.8 against a narrative fair value of DKK416, the story hinges on whether its obesity pipeline and funding base justify that gap.
The growing focus on combination and multi-mechanism obesity drugs (e.g., amylin plus incretin combinations) and accelerated regulatory pathways for innovative peptides aligns with Zealand's core expertise and pipeline, creating opportunities to capture outsized value from industry investment momentum and delivering upside to projected long-term net income as new products reach market.
See why 27 investors see Zealand Pharma as 45% undervalued.
Result: Fair Value of DKK416 (UNDERVALUED)
Still, analyst confidence in Zealand Pharma’s upside could be challenged if key obesity trials disappoint or if partnership milestones arrive more slowly than expected.
Find out about the key risks to this Zealand Pharma narrative.
Next Steps
The mixed tone around Zealand Pharma’s prospects only matters if you test the assumptions yourself. Move quickly, review the underlying data and weigh both sides of the 1 key reward and 2 important warning signs.
Looking for more investment ideas beyond Zealand Pharma?
If you stop at Zealand Pharma, you risk missing other opportunities that fit your style and could suit your portfolio just as well.
- Target stronger value potential by checking out 188 high quality undervalued stocks that combine resilient fundamentals with prices that may not fully reflect their financial profile.
- Strengthen portfolio resilience and sleep easier by scanning a 228 resilient stocks with low risk scores that score well on balance sheet and volatility checks.
- Get ahead of the crowd by reviewing a list of solid balance sheet and fundamentals (202 results) before they attract wider attention and pricing becomes less forgiving.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com